NASDAQ:MBII - Marrone Bio Innovations Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.59 -0.03 (-1.85 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$1.59
Today's Range$1.57 - $1.65
52-Week Range$1.10 - $3.39
Volume119,966 shs
Average Volume117,572 shs
Market Capitalization$176.00 million
P/E Ratio-7.57
Dividend YieldN/A
Beta-0.14
Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. The company's products include Regalia, a plant extract-based fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants. It also provides Zequanox, a biomolluscicide that controls invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies; and Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes. In addition, the company offers Haven, an sun protectant product that reduces plant stress and dehydration; and Majestene and Zelto, a bionematicide to control soil-dwelling nematodes by preventing and reducing root galls, as well as reducing adult reproduction and egg hatch. Further, it provides Stargus and Amplitude, a biofungicide for improving plant health. Marrone Bio Innovations, Inc. provides its products directly through sales force, as well as through distributors. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was founded in 2006 and is headquartered in Davis, California.

Receive MBII News and Ratings via Email

Sign-up to receive the latest news and ratings for MBII and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
Current SymbolNASDAQ:MBII
CUSIPN/A
Phone530-750-2800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.22 million
Book Value($1.62) per share

Profitability

Net Income$-20,210,000.00

Miscellaneous

EmployeesN/A
Market Cap$176.00 million
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable

Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions

What is Marrone Bio Innovations' stock symbol?

Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations Inc (NASDAQ:MBII) announced its quarterly earnings results on Tuesday, August, 14th. The basic materials company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The basic materials company had revenue of $5.75 million for the quarter, compared to analyst estimates of $7.01 million. Marrone Bio Innovations had a negative return on equity of 102.54% and a negative net margin of 95.26%. View Marrone Bio Innovations' Earnings History.

When is Marrone Bio Innovations' next earnings date?

Marrone Bio Innovations is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Marrone Bio Innovations.

What price target have analysts set for MBII?

2 brokerages have issued twelve-month target prices for Marrone Bio Innovations' stock. Their forecasts range from $2.50 to $3.00. On average, they expect Marrone Bio Innovations' stock price to reach $2.75 in the next year. This suggests a possible upside of 73.0% from the stock's current price. View Analyst Price Targets for Marrone Bio Innovations.

What is the consensus analysts' recommendation for Marrone Bio Innovations?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marrone Bio Innovations.

What are Wall Street analysts saying about Marrone Bio Innovations stock?

Here are some recent quotes from research analysts about Marrone Bio Innovations stock:
  • 1. National Securities analysts commented, " Q4 Revenues Beat Consensus. Revenue of $5.7 million came in ahead of consensus estimates of $4.8 million, representing growth of 72% on a year-over-year basis. Excluding the impact of non-recurring, non-operating expenses, a net loss of $0.05 per share narrowly missed our estimate of $0.04 per share.
     Seed Treatment Business Delivering. Management noted the contributions from the Venerate family of products was a major growth driver during the quarter, especially when applied as seed treatment. We believe the seed treatment agreement with Albaugh represents the single largest growth driver for MBII and could be a $10 million contributor by 2020.
     OpEx Ticks Upward. SG&A and R&D came in roughly flat on a full year basis from 2017 to 2018 but ticked up in the fourth quarter. Investments to accelerate the launch of MBI-014 and in additional headcount in the sales force look to increase OpEx on a full year basis in 2019. We model revenue growth in 2019 of 42% to outpace growth of 10% in OpEx.
     Multiple Catalysts Converging In 2019. The ramping of the seed treatment business, acceleration of cannabis revenues, growth in international markets and maturation of the sales force all suggest to us that the momentum MBII ended the year with should continue into 2019. We are raising our 2019 revenue estimate from $28.5 million to $30.0 million.
     Organic Growth Rates Ahead of Agricultural Peers. We estimate organic growth of 42% in 2019, which is the highest rate of any agricultural peer we consider with an established product line. Importantly, the primary drivers have long legs, and we believe the company can grow from a $21 million business in 2018 to a $100 million business by 2023." (3/15/2019)
  • 2. According to Zacks Investment Research, "Marrone Bio Innovations Inc. develops environmentally safe bio-based products. The Company specializes in the discovery, development, and marketing of natural products for weed, pest, water resource, and plant disease management. It offers crop protection products for conventional and organic crop production, including herbicides for weed control, fungicides for plant disease control, nematicides for parasitic roundworm control, insecticides for insect and mite killers and plant growth regulators that growers use to increase crop yields, enhance plant health, manage pest resistance, and reduce chemical residues. Marrone Bio Innovations Inc. is headquartered in Davis, California. " (11/29/2018)
  • 3. HC Wainwright analysts commented, "We are lowering our price target on MBII to $2.50, from $3.50 previously, driven by: (1) effect of salesforce attrition, experienced earlier in 2018, that has continued to negatively impact the pace of topline revenue growth; (2) slower than expected regulatory approval process for the company’s bioinsecticides, biofubgicides, and biopesticides.; and (3) longer than expected sales cycles. We are now taking a slightly more conservative stance on our forward projections for MBII, resulting in the lowered price target. Please see the valuation section of this note for more details. 3Q18 results overview. 2018, MBII reported revenues of $5.4M for the quarter (28.6% YoY increase). Gross margins were 48.3% for the quarter, compared to 40.9% in the year ago period." (11/14/2018)

Has Marrone Bio Innovations been receiving favorable news coverage?

News coverage about MBII stock has trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Marrone Bio Innovations earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave media coverage about the basic materials company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the near term.

Who are some of Marrone Bio Innovations' key competitors?

What other stocks do shareholders of Marrone Bio Innovations own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marrone Bio Innovations investors own include Denali Therapeutics (DNLI), Micron Technology (MU), Canopy Growth (CGC), Cronos Group (CRON), 22nd Century Group (XXII), General Electric (GE), Genocea Biosciences (GNCA), Magnegas Applied Tchnlgy Sltns (MNGA), Gevo (GEVO) and Yield10 Bioscience (YTEN).

Who are Marrone Bio Innovations' key executives?

Marrone Bio Innovations' management team includes the folowing people:
  • Dr. Pamela G. Marrone, Founder, CEO & Director (Age 62)
  • Mr. James B. Boyd, Pres & CFO (Age 66)
  • Ms. Linda V. Moore, Chief Compliance Officer, Gen. Counsel, Exec. VP & Sec. (Age 72)
  • Dr. Amit Vasavada Ph.D., Sr. VP of R&D and CTO (Age 64)
  • Andre Trepanier, Director of Marketing

Who are Marrone Bio Innovations' major shareholders?

Marrone Bio Innovations' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.53%), Geode Capital Management LLC (0.40%), Geode Capital Management LLC (0.40%), Rhumbline Advisers (0.06%) and Paloma Partners Management Co (0.04%). Company insiders that own Marrone Bio Innovations stock include Ardsley Advisory Partners, Van Herk Investments BV and Waddell & Reed Financial Inc. View Institutional Ownership Trends for Marrone Bio Innovations.

Which institutional investors are buying Marrone Bio Innovations stock?

MBII stock was acquired by a variety of institutional investors in the last quarter, including Paloma Partners Management Co, Geode Capital Management LLC, Geode Capital Management LLC, Rhumbline Advisers and BlackRock Inc.. Company insiders that have bought Marrone Bio Innovations stock in the last two years include Ardsley Advisory Partners, Van Herk Investments BV and Waddell & Reed Financial Inc. View Insider Buying and Selling for Marrone Bio Innovations.

How do I buy shares of Marrone Bio Innovations?

Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marrone Bio Innovations' stock price today?

One share of MBII stock can currently be purchased for approximately $1.59.

How big of a company is Marrone Bio Innovations?

Marrone Bio Innovations has a market capitalization of $176.00 million and generates $21.22 million in revenue each year. The basic materials company earns $-20,210,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

What is Marrone Bio Innovations' official website?

The official website for Marrone Bio Innovations is https://marronebioinnovations.com.

How can I contact Marrone Bio Innovations?

Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at 530-750-2800 or via email at [email protected]


MarketBeat Community Rating for Marrone Bio Innovations (NASDAQ MBII)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  357
MarketBeat's community ratings are surveys of what our community members think about Marrone Bio Innovations and other stocks. Vote "Outperform" if you believe MBII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBII will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Featured Article: Balanced Fund

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel